Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
Date: September 23, 2019
Issue #:
1581Summary:
Lefamulin (Xenleta– Nabriva), a semisynthetic
pleuromutilin antibiotic, has been approved by the
FDA for IV and oral treatment of community-acquired
bacterial pneumonia (CABP) in adults. It is the first
systemic pleuromutilin antibiotic to be approved in the
US; retapamulin(Altabax), a 1% topical ointment for
treatment of impetigo, was approved in 2007.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Amoxicillin Ampicillin/sulbactam Avelox Azithromycin Cefotaxime Cefpodoxime ceftaroline Ceftriaxone Chlamydophila pneumoniae Doxycycline Fluoroquinolones Haemophilus influenzae lefamulin Levaquin Levofloxacin Linezolid meth Source Type: research
More News: Amoxicillin | Avelox | Azithromycin | Bacterial Pneumonia | Ceftriaxone | Chlamydophila | Chlamydophila pneumoniae | Doxycycline | Drugs & Pharmacology | Haemophilus Influenzae (Hib) | Impetigo | Levaquin | Linezolid | Moxifloxacin | Pneumonia | Rocephin | Zithromax | Zyvox